ABSTRACT: Studies using xenograft mouse models have shown that plasma applied to the skin overlying tumors results in tumor shrinkage. Plasma is considered a nonpenetrating treatment; however, these studies demonstrate plasma effects that occur beyond the postulated depth of physical penetration of plasma components. The present study examines the propagation of plasma effects through a tissue model using three-dimensional, cell-laden extracellular matrices (ECMs). These ECMs are used as barriers against direct plasma penetration. By placing them onto a monolayer of target cancer cells to create an in-vitro analog to in-vivo studies, we distinguished between cellular effects from direct plasma exposure and cellular effects due to cell-to-cell signaling stimulated by plasma. We show that nanosecond-pulsed dielectric barrier discharge plasma treatment applied atop an acellular barrier impedes the externalization of calreticulin (CRT) in the target cells. In contrast, when a barrier is populated with cells, CRT externalization is restored. Thus, we demonstrate that plasma components stimulate signaling among cells embedded in the barrier to transfer plasma effects to the target cells.
I. INTRODUCTION
In the past decade, nonthermal plasma has emerged as a potential antitumor therapy due to its selectivity to adversely affect tumor cells compared to healthy cells. [1] [2] [3] [4] Both in-vitro and in-vivo -spheric pressure plasma jets (APPJ), dielectric barrier discharges (DBDs), and plasma-activated media (PAM). [5] [6] [7] [8] [9] For treatment of subcutaneous tumors in vivo, jets and DBDs generate plasma on the overlying skin, resulting in shrinkage of tumors one order of magnitude deeper than the theoretical penetration depth of plasma (1 mm vs 0.05 mm). 10, 11 The mechanism by which plasma penetrates through this tissue to selectively affect the tumors underneath is unclear but critical to understand for clinical use of plasma. 4 For the application of plasma-based therapy, the depth of penetration of treatment will determine whether the therapy is applicable to deep tumors as well. As shown in Fig. 1 , nspDBD treatment of porcine skin recruited immune cells to the treatment site. Both plasma-treated and untreated skin tissue were stained for CD163, an immune cell marker, 1 wk after plasma treatment. The presence of recruited cells beneath the skin shows evidence that plasma, widely considered a surface treatment modality, can interact with the surface tissue to affect cells deep into the tissue. 12 A proposed pathway for cancer treatment using plasma is the stimulation of immune cells to target and eliminate tumors. 13 Although multiple approaches to immunotherapy exist, the uniqueness of plasma is its ability to noninvasively and simultaneously stimulate the immune cells while selectively stressing tumor cells.
14-16 Nanosecond-pulsed dielectric barrier discharge (nspDBD) plasma treatment has enhanced macrophage function directly. 17, 18 It has also induced immunogenic cell death (ICD) in cancer cells in vitro. Additionally, in a coculture system, signals released from tumor cells under-14 This mechanism is even more selective, because stimulated immune cells will recognize and remove cancer cells but leave the healthy cells unaffected. 13 Our recent in-vivo studies use nspDBD plasma for treatment of subcutaneous colorectal tumors through the proposed immunotherapy mechanism. 13, 19 To determine how nspDBD plasma can penetrate the overlying tissue to induce ICD in the tumor, -mensional (3D) extracellular matrix (ECM) representing the tissue in vitro. 20 The tissue model is placed on top of a monolayer of cancer cells, mimicking a tissue layer between plasma components and the tumor. NspDBD treatment was applied to the surface of the barrier and responses in the cancer cells below were measured.
II. MATERIALS AND METHODS

A. Cell Culture, Cells to Cells
Cell of the mouse colorectal cancer cell line CT26 (a gift from Dr. Adam Snook, department of pharmacology, Thomas Jefferson University, Philadelphia, PA) were grown in incubated at 37ºC with 5% CO 2 .
B. Tissue Model Fabrication and Culture
mechanics, Drexel University, Philadelphia, PA. The original method was tailored for -2 pores. 
C. nspDBD Plasma Treatment
Atmospheric pressure plasma was generated using an nsp power supply (FPB-20-05NM; FID GmbH; Burbach, Germany). As done in previous work, the pulser generated a 29-kV pulse with a rise time of 2 ns and pulse width of 20 ns. 14 A function mm, respectively. The energy per pulse for a 24-well plate was found to be 0.9 mJ/ pulse. 14 One day before plasma treatment, CT26 cells were seeded in 24-well plates with plasma by removing the PBS, applying the plasma at the 1-mm gap distance, and treatment, PBS was removed from both the cells and barrier, and the barrier was lifted with forceps and placed gently in the center of the well on top of the cells. Plasma was 2D and 3D plasma-treated cell cultures were incubated for 24 hr at 37ºC with 5% CO 2 following plasma treatment.
D. Extracellular ATP Measurement
was measured as described previously.
14 -lular ATP, the light generated during the chemical reaction between a bioluminescent ATP mix stock and buffer were combined to create a working solution that was then after adding the working solution.
E. Ecto-Calreticulin Measurement
bated for 24 hr after plasma treatment. The barriers were detached from the monolayer were collected and prepared for staining. Primary (PA3-900 CRT Polyclonal; Thermo
F. Fluorescence Imaging
and Mg at 10-min intervals and stored in PBS without Ca and Mg. To process the sample in PBS without Ca and Mg for 30 min. After washing thrice in 10-min intervals with -tion for 30 min. Samples were washed two more times in 10-min intervals and stained for nucleic acid using 400 pM M phalloidinOnce stained, samples were washed thrice at 10-min intervals. Before loading onto the similarly to the fabrication setup. Images were taken using confocal microscopy (SP5;
G. Statistical Analyses
Data were analyzed through one-way analysis of variance (ANOVA) parametric tests were tested against the controls of similar experimental design, for example, treated cell-laden barriers were compared with control cell-laden barriers. Samples are plotted using mean and standard deviation, with n
III. RESULTS AND DISCUSSION
A monolayer of CT26 cells was treated with nspDBD plasma in the presence or absence of a barrier to evaluate the depth of penetration of plasma treatment. The expression of ecto-CRT, a marker for the initiation of ICD, in the monolayer was used to indicate whether plasma effects reached the cells below the barrier. 22 Plasma interacts with cells in the barrier through the direct diffusion of plasma components (UV radiation, reacstress, and stimulates redox-based signaling responses in both cancerous and healthy cells.
23,24 Plasma-generated reactive species have limited half-lives and diffusion distances, which are theorized to limit the depth of plasma treatment effect. 2 To distinguish between tumor cell responses to plasma components and to a combination of plasmastimulated intercellular signaling and components, the barriers were acellular or loaded with cells, respectively.
A. nspDBD Plasma Treatment Induces Ecto-CRT Expression in CT26
Cancer Cells
A baseline of ecto-CRT expression in CT26 colorectal cancer cells was established in cells grown and treated in the absence of a barrier. Cells were collected 24 hr after plasma treatment and stained for CRT. Plasma treatment at 300 mJ increased the externalization of CRT on cells from 7.5% to 16.8% (Fig. 3A) . This result, a twofold increase in the expression of ecto-CRT, compares to our previous studies at the same energy. 14 In subsequent studies, this served as a positive control to determine whether plasma treatment penetrated the tissue model to affect cells underneath.
B. nspDBD Plasma Treatment atop an Acellular Barrier Impedes Component Diffusion
To investigate whether plasma components penetrate to affect ecto-CRT levels on tumor cells, we used a tissue model as a barrier and evaluated the cellular response in the monolayer below. Treatment at the same energy as that of the positive control resulted in a negligible increase to 7.8% from 7.5% ecto-CRT positive population (Fig. 3B ). This suggests that plasma components generated at 300 mJ are unable to pass through the could. To assess whether CRT expression increased with increasing energy, the experiment was repeated with treatments at 700, 900, and 2000 mJ, which resulted in partial recovery even at the highest energy tested. Although this shows that plasma components penetrate further with higher energy, the energy required is too high to be safe for biological tissue. 
C. Plasma-Stimulated Intercellular Signaling from the Barrier Increases Plasma Depth of Penetration
The externalization of CRT through the depth of the tumor has been documented in animal studies. 25, 26 In other studies, Drosophila larvae treated with plasma exhibited an increase in fully differentiated hemocytes without any damage or change in physiology and life cycle. 27 This suggests that although plasma components may not penetrate, biological signaling may facilitate transfer of plasma effect. Therefore, we populated the on CRT induction in the target cells. The addition of cells to the barrier was expected to cause plasma components to interact with the embedded cells. Any effect on the target cells below would presumably be a result of cell-to-cell communication. Treatment atop the cell-laden barrier increased the percentage of cells with ecto-CRT expressed from 7.5% to 9.95% at 300 mJ. This indicates that the presence of cells enabled the plasma is more evident with higher-energy plasma because the percentage of CRT-positive cells is higher at both 900 mJ (19.27%) and 2000 mJ (22.82%) than at the positive control (16.8%) (Fig. 3C) . In comparison to the acellular barrier treated at the same plasma energies, the addition of cells to the barrier allowing for intercellular signaling resulted in higher ecto-CRT expression in the monolayer. In conclusion, plasma-stimulated intercellular signaling can increase the antitumor effects of plasma treatment.
D. nspDBD Plasma Treatment Induces Immediate ATP Release from Cells in the Barrier and Monolayer
Increased CRT expression in target cells showed that plasma might affect cells underneath the cell-laden barrier; however, the mechanism and plasma components responsible were still unclear. The typical reaction time for the expression of ecto-CRT in response to ICD inducers is a few hours after treatment, which is orders of magnitude longer than the lifetime of the plasma components. 2, 28 Thus, to study the immediate direct effects of plasma treatment, we measured the extracellular ATP concentration. It was previously shown that nspDBD plasma causes cancer cells to release ATP within 10 min after treatment. 14 The concentration of extracellular ATP released in response to plasma treatment at 300 mJ was established in the monolayer. The amount of plasma treatment increased the mea-M M (Fig. 4A) . With the addition of the acellular barrier and treatment at 2000 mJ, measured ATP was 1.84 M, suggesting that the barrier impedes plasma components from penetrating target cells. Plasma treatment atop the cell-laden barrier at 2000 mJ resulted in an ATP value of 2.99 M, comparable to the amount of ATP released with treatment of the monolayer. Although this seems to indicate that plasma-stimulated intercellular signaling can stimulate target cells to release more ATP (comparable to the positive control), this is not the case. When the cell-laden barrier was treated at 2000 mJ without target cells below, the measured ATP M (Fig. 4A ). This indicates that the cells embedded in the barrier contribute M) when evaluated in the presence of basal target cells. This shows that both the cells embedded in the barrier and the target cells react to plasma more quickly than the CRT response would indicate.
(nspEFs), a component of nspDBD plasma, are theorized to assist in the penetration of tissue and disruption of cellular membranes. 29 To examine the the nspEF was applied. The breakdown voltage for liquid is one order of magnitude 30 The concentrations of ATP released were 491.5 and 589.8 nM for the acellular and cell-laden barrier, respectively (Fig. 4B) . The nspEF-induced release of ATP was marginal in comparison to the concentration released in response to plasma. Although the ATP released originates from target cells in the acellular barrier case, it is indistinguishable whether cells in the barrier and/or target cells release ATP.
E. Transfer of Plasma-Induced CRT Expression Relies on Cell Proximity
For in-vivo xenograft models, the propagation distance of antitumor effects from the skin to the tumor below is further than the penetration depth of plasma-generated species.
11 This observation suggests a contribution of intercellular signaling. Signal transfer between two cells occurs after an activation of various factors from one cell to its neighbors (paracrine signaling) and/or through direct cell-to-cell contact signaling, such as occurs in gap junctions. 31 The cell-laden barrier data suggest that plasma components penetrate the tissue model and interact with cells within the barrier to stimulate subsequent signaling events. To assess whether paracrine signaling was the dominant signaling mechanism for inducing ecto-CRT expression in target cells, the cell-laden barrier was treated in a separate well before transfer, to prevent any immediate, direct contact with plasma components that could affect target cells. After the barrier was transferred to the monolayer and incubated for 24 hr, CRT expression was measured. The observed response in the CT26 cells was 11.49% at 2000 mJ (Fig. 5) , which compares to the value of control without plasma treatment (10.65%). This indicates that paracrine signaling alone cannot sustain the transfer of effect and requires a close proximity between cells.
For the transfer of signals through direct contact, such as through gap junctions, the embedded cells should form connections with their cytoskeleton. 32 To examine whether -skeleton to identify nuclei and cytoskeletal junctions, respectively. As shown in Fig. 6 , the cytoskeleton surrounding the nuclei of the cells connects to form a network capable of signal propagation. Therefore, signal transfer through gap junctions could be a likely pathway in this tissue model and merits further investigation.
F. Calcium Wave Propagation
of plasma. 32 The mechanism of calcium-induced calcium release (CICR) requires both paracrine and direct contact signaling to propagate a wave of intracellular calcium among cells.
Studies have shown that plasma treatment of cancer cells increases intracellular calcium concentration. 35, 36 Calcium can signal to nearby cells by inducing release of ATP or by itself being transferred through junctions to adjacent cells (Fig. 7) . Released ATP degrades rapidly; thus, it will only signal to nearby cells. ATP binds to purinergic receptors on the cell membrane, which induces release of calcium from the endoplasmic reticulum (ER) and increases intracellular calcium concentration. 37 This supports our model, because the induction of surface CRT expression is favored when calcium in the ER is depleted.
38
ger ER calcium release, propagation due to paracrine signaling ceases. Excess calcium will also propagate as a wave among cells via gap junctions. 33 If the concentration of intracellular calcium is adequate, calcium can signal the release of ATP from cells that are not directly treated with plasma. Therefore, plasma treatment induces stress that can cause cells to propagate a gradient of intracellular calcium through CICR. This results in expression of surface CRT and release of ATP. We plan to test this hypothesis in future studies using inhibitors and signal blocking agents.
IV. CONCLUSION
This study reports on the enhanced propagation of plasma-stimulated antitumor effects through intercellular signaling in a tissue model. Indications of plasma treatment affect-
FIG. 7:
CICR propagation of surface CRT expression. Plasma-induced calcium increase can be propagated from cell to cell via paracrine and direct contact signaling. The released ATP in response to plasma can signal nearby cells by binding to surface purinergic receptors, raising the calcium concentration. However, extracellular ATP rapidly degrades, limiting the propagation distance due to paracrine signaling. A calcium increase triggered in this way originates from the travel as a wave among adjacent cells through direct contact signaling, reaching cells that cannot --erating the paracrine signaling propagation. Therefore, CICR propagation may be the mechanism for propagating plasma-stimulated effects.
ing target tumor cells, expression of ecto-CRT, and release of ATP were higher in cancer cells beneath a cell-laden barrier than cells under an acellular barrier. This suggests that cells in the barrier responded to plasma treatment by enhancing the propagation of ICDinducing factors to affect target cancer cells. Additionally, increasing plasma energy caused more of these factors (including both the components and intercellular signals) to reach the cells beneath the barriers, indicating that higher energies increase the depth of penetration of plasma treatment. Our future studies will address the maximum depth of penetration of individual plasma components and whether CICR is the signaling of noninvasive cancer treatment that selectively affects tumor cells over healthy tissue and minimizes the potential for adverse side effects. 
